AA amyloidosis arising in the context of a chronic inflammatory joint disease or inflammatory bowel disease presents a distinct clinical challenge: the sustained inflammatory burden that drives amyloid deposition must be addressed directly to halt disease progression.

Clinical Scenario

AA amyloidosis associated with an inflammatory joint disease or inflammatory bowel disease — a setting in which ongoing systemic inflammation fuels amyloid accumulation and progressive kidney injury, with worsening proteinuria as a key measurable consequence.

Treatment Approach & Goals

The treatment strategy focuses on immunomodulatory therapy directed at the underlying inflammatory disease, encompassing both conventional immunosuppressive agents and targeted biologic options. The primary clinical goal is control of the progression of amyloidosis-associated proteinuria.

The complete regimen — including agent selection, sequencing, and monitoring parameters — is available in the full structured protocol below.

References

DOI: 10.2147/CLEP.S39981

Finally, immunomodulatory drugs have also proven extremely useful in controlling the progression of amyloidosis-associated proteinuria and improving long-term survival in several inflammatory joint diseases and in inflammatory bowel disease.

Although an in-depth analysis of each of these drugs is well beyond the scope of this review, they include, but are not limited to, chlorambucil, cyclophosphamide, tacrolimus, and anti-TNF-alpha or anti-IL-6 antibodies, such as infliximab, etanercept, or tocilizumab.

View source ↗

Treatment of AA Amyloidosis in Inflammatory Joint Disease or Inflammatory Bowel Disease

Clinical Scenario

Treatment Approach & Goals

References